首页> 外文期刊>International journal of gynecological pathology: Official journal of the International Society of Gynecological Pathologists >Expression of poly (adenosine diphosphate-ribose) polymerase and p53 in epithelial ovarian cancer and their role in prognosis and disease outcome.
【24h】

Expression of poly (adenosine diphosphate-ribose) polymerase and p53 in epithelial ovarian cancer and their role in prognosis and disease outcome.

机译:聚腺苷二磷酸核糖聚合酶和p53在卵巢上皮癌中的表达及其在预后和疾病预后中的作用。

获取原文
获取原文并翻译 | 示例
       

摘要

PARP, poly (adenosine diphosphate-ribose) polymerase, is a damage-sensing protein, which is essential for the repair of DNA single-strand breaks. PARP and p53 function synergistically in repairing DNA damage and suppressing chromosomal rearrangements. The aim of this study was to determine the expression of PARP and p53 in epithelial ovarian cancer (EOC) and to correlate their expression with clinicopathologic characteristics. PARP and p53 were evaluated using immunohistochemistry applied on a tissue microarray of 189 EOC and their expressions were correlated to clinicopathologic variables, including the age of diagnosis, stage, grade, histologic type, optimal debulking, progression-free survival, and overall survival (OS). PARP and p53 expressions were shown in 61% and 54% of cases, respectively. PARP-positive tumors are more likely to have higher grade (P=0.03) and complete response to initial first-line chemotherapy (P=0.009). Patients with positive p53 staining are more likely to be at the advanced stage disease (P=0.004). Finally, there were no significant associations between PARP and p53 expression and no differences in progression-free survival and OS for PARP or p53 expressions. The overexpression of PARP and p53 in high grade, and advanced stage tumors indicated that these 2 markers might serve as an indicator of aggressive disease behavior. Additional studies are warranted to evaluate the role of PARP and PARP inhibitors in the setting of adjuvant chemotherapy.
机译:PARP是一种聚腺苷二磷酸核糖聚合酶,是一种损伤敏感蛋白,对于修复DNA单链断裂至关重要。 PARP和p53在修复DNA损伤和抑制染色体重排方面具有协同作用。这项研究的目的是确定PARP和p53在上皮性卵巢癌(EOC)中的表达并将其表达与临床病理特征相关联。使用在189 EOC的组织芯片上进行的免疫组织化学对PARP和p53进行评估,其表达与临床病理变量相关,包括诊断年龄,分期,等级,组织学类型,最佳减瘤,无进展生存期和总生存期(OS) )。 PARP和p53表达分别在61%和54%的病例中显示。 PARP阳性的肿瘤更有可能具有较高的等级(P = 0.03)和对初始一线化疗的完全反应(P = 0.009)。 p53染色阳性的患者更有可能处于晚期疾病(P = 0.004)。最后,PARP和p53表达之间没有显着的关联,PARP或p53表达的无进展生存期和OS也无差异。在高级别和晚期肿瘤中PARP和p53的过度表达表明这两种标记可能是侵略性疾病行为的指示。必须进行其他研究来评估PARP和PARP抑制剂在辅助化疗中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号